Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

MCI and gut microbiome

ABSTRACT: Modulation of the gut microbiome in Mild Cognitive Impairment (MCI) subjects

PROVIDER: PRJEB32675 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	ERR3346990_1.fastq.gz	Fastqsanger.gz
	ERR3346990_2.fastq.gz	Fastqsanger.gz
	ERR3347000_1.fastq.gz	Fastqsanger.gz
	ERR3347000_2.fastq.gz	Fastqsanger.gz
	ERR3347010_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 186

Similar Datasets

Proteins present in tears from control, MCI and Alzheimer disease patients

Project description:we investigated tear fluid as a novel source of disease-specific protein biomarkers for Alzheimer disease (AD) development using samples from patients suffering from mild cognitive impairment (MCI) and AD. Tear protein content was evaluated via liquid chromatography–mass spectrometry.

2019-11-04 | PXD014475 | Pride

RNA sequencing of AD, MCI and control OM cells

Project description:Total RNA sequencing of cultured OM cells derived from patients with Alzheimer's disease (AD), individuals with mild cognitive impairment (MCI) and cognitively healthy controls.

| EGAS00001006195 | EGA

Alzheimer, MCI and control samples from AddneuroMed Cohort (batch 1)

Project description:Alzheimer case-control samples originate from the EU funded AddNeuroMed Cohort, which is a large cross-European AD biomarker study relying on human blood as the source of RNA. The design is case-control. Cases are either Alzheimer's disease patients, subjects with mild cognitive impairment or age and gender matched controls.

2015-08-05 | E-GEOD-63060 | biostudies-arrayexpress

RNA sequencing of AD, MCI and control ONS cells

Project description:We have generated human olfactory neurosphere-derived (ONS) cells from individuals with AD or mild cognitive impairment (MCI), and their cognitively healthy controls, and performed global RNA sequencing to determine gene expression changes in ONS cells.

| EGAS00001006594 | EGA

Circulating microRNAs associated to cerebrospinal fluid amyloid-β and phosphorylated tau levels as potential non-invasive biomarkers for mild cognitive impairment and Alzheimer’s disease

Project description:To identify the potential biomarkers of Alzheimer's disease (AD) based on circulating microRNAs (miRNAs), we developed a new approach using feature selection and linear mixed model. The miRNA sequencing data of 105 plasma and 112 serum samples from 112 subjects including 28 AD cases, 63 mild cognitive impairment (MCI), and 21 controls were used to identify cerebrospinal fluid biomarkers associated miRNAs. The potential of these miRNAs as biomarkers of AD or MCI was researched and validated via both internal and external dataset. Patient classification was effectuated in compliance with the NIA-AA criteria for “MCI due to AD” and “Dementia due to AD”.

2024-02-26 | GSE215789 | GEO

Co-expression network analysis of frontal cortex during the progression of Alzheimer’s disease

Project description:Using WGCNA and enrichment analyses to identify pathway level differences between individuals with no cognitive impairment, mild cognitive impairment, and Alzheimer’s disease. Frozen frontal cortex (BA10) tissue from NCI, MCI, and mild/moderate AD cases (n = 12/group) representing both genders was acquired postmortem from participants in the Rush Religious Orders Study, a longitudinal clinical pathologic study of aging and AD in elderly Catholic clergy

2021-10-15 | GSE185909 | GEO

Changes in cognitive ability and serum microRNAs during aging in mice

Project description:Mild cognitive impairment (MCI) is considered an early stage leading to dementia. MCI can be reversed, and early diagnosis at the MCI stage is vital to control the progression to dementia. Dementia is currently diagnosed based on interviews and screening tests. However, novel biomarkers must be identified to enable early detection of MCI. Therefore, this study aimed to discover novel biomarkers in the form of blood microRNAs (miRNAs) for the diagnosis of MCI or early dementia.

2023-12-06 | GSE249248 | GEO

Mikrobiom HC to MCI

Project description:Prognostic value of gut microbiome for progression from normal cognition to mild cognitive impairment within 4 years

| PRJEB85717 | ENA

RNA-seq of human plasma microRNAs in Alzheimer Disease

Project description:MicroRNAs (miRNAs) could play an important role as potential Alzheimer Disease (AD) biomarkers. Plasma samples were collected from participants: Mild cognitive impairment (MCI) due to AD patients (n= 20), preclinical AD patients (n= 8) and healthy controls (n= 20). Then, small RNA sequencing analysis, followed by miRNA differential expression analysis comparing different methods (DESeq2, edgeR, NOISeq) were carried out.

2022-05-08 | E-MTAB-11103 | biostudies-arrayexpress

Prognosis prediction model for Alzheimer’s disease conversion from mild cognitive impairment by integrative analysis of multi-omics data

Project description:Mild cognitive impairment (MCI) is a clinical precursor of Alzheimer’s disease (AD). Many MCI subjects convert to AD, although others remain stable as MCI or sometimes return to cognitive normal. Currently, there are no curative treatments for patients who are already in AD, and therefore biomarkers for early detection of high risk MCI-to-AD conversion subjects are rapidly required. Here, we investigated potential biomarkers from blood-based miRNA (miR) expression profiles and genomic data of 197 Japanese MCI patients. Using the candidate biomarkers, we constructed a prognosis prediction model based on a Cox proportional hazard model. The final prediction model, composed of 24 miR-eQTLs (i.e. SNP-miRNA pairs) and three clinical factors (age, sex and ApoE ε4 carriers), successfully classified MCI patients into two groups, low and high, in terms of risk of MCI-to-AD conversion (log-rank trend test P=3.44×10^(-4)), and achieved a concordance index of 0.702 on an independent test set. Network-based meta-analysis using target genes of the miR-eQTLs further revealed four important hub genes (SHC1, FOXO1, GSK3B, and PTEN) associated with the pathogenesis of AD. Statistically significant differences were observed in PTEN expression between MCI and AD and SHC1 expression between cognitively normal elder subjects (CN) and AD when examining RNA-seq data from 610 blood samples (PTEN, P=0.023; SHC1, P=0.049), although FOXO1 and GSK3B showed low levels of expression in blood. Accurate prediction of MCI-to-AD conversion enables earlier appropriate intervention for those MCI patients and can lead to a reduction of MCI patients that convert to AD with high risk. We believe that further investigation with larger sample sizes will contribute to practical clinical use of our approach in MCI-to-AD conversion in the near future.

2020-11-11 | GSE150693 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data